Pharmaceuticals & Biotechnology
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 11% is a good sign.
Size: It is a very small market cap company. Risks of volatility, governance, sustained growth assumptions should be double checked.
Technicals: SharesGuru indicator is Bearish.
Past Returns: In past three years, the stock has provided 10.5% return compared to 13.6% by NIFTY 50.
Momentum: Stock is suffering a negative price momentum. Stock is down -18.6% in last 30 days.
Growth: Poor revenue growth. Revenue grew at a disappointing -12.5% on a trailing 12-month basis.
Valuation | |
|---|---|
| Market Cap | 54.82 Cr |
| Price/Earnings (Trailing) | 17.77 |
| Price/Sales (Trailing) | 1.56 |
| EV/EBITDA | 9.74 |
| Price/Free Cashflow | -8.62 |
| MarketCap/EBT | 10.35 |
| Enterprise Value | 58.98 Cr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 35.09 Cr |
| Rev. Growth (Yr) | 2.1% |
| Earnings (TTM) | 3.88 Cr |
| Earnings Growth (Yr) | -33.5% |
Profitability | |
|---|---|
| Operating Margin | 17% |
| EBT Margin | 15% |
| Return on Equity | 9.92% |
| Return on Assets | 8.06% |
| Free Cashflow Yield | -11.61% |
Growth & Returns | |
|---|---|
| Price Change 1W | -5% |
| Price Change 1M | -18.6% |
| Price Change 6M | -15.7% |
| Price Change 1Y | -42.1% |
| 3Y Cumulative Return | 10.5% |
| 5Y Cumulative Return | 14.4% |
| 7Y Cumulative Return | 20.6% |
| 10Y Cumulative Return | 16.6% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | 45.95 L |
| Cash Flow from Operations (TTM) | -5.83 Cr |
| Cash Flow from Financing (TTM) | 1.35 Cr |
| Cash & Equivalents | 1.19 Cr |
| Free Cash Flow (TTM) | -6.25 Cr |
| Free Cash Flow/Share (TTM) | -19.68 |
Balance Sheet | |
|---|---|
| Total Assets | 48.15 Cr |
| Total Liabilities | 9.03 Cr |
| Shareholder Equity | 39.11 Cr |
| Current Assets | 45.47 Cr |
| Current Liabilities | 8.08 Cr |
| Net PPE | 2.54 Cr |
| Inventory | 2.58 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.11 |
| Debt/Equity | 0.14 |
| Interest Coverage | 13.63 |
| Interest/Cashflow Ops | -16.93 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 2 |
| Dividend Yield | 1.16% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Summary of Vasundhara Rasayans's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Understand Vasundhara Rasayans ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| P & J CRETECHEM PRIVATE LIMITED | 61.98% |
| GARG LEASING AND FINANCE PRIVATE LIMITED | 3.55% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Vasundhara Rasayans against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.